Insiders Theriva Biologics, Inc.

Equities

TOVX

US87164U4094

Market Closed - Nyse Other stock markets 16:10:00 2024-05-20 EDT			5-day change	1st Jan Change
0.37 ^USD	-0.19%		-1.10%	-13.97%

05-07	Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-23	Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Theriva Biologics Appoints Ramon Alemany as Senior VP of Discovery	23-05-23	CI
Synthetic Biologics, Inc. has Changed its Name to Theriva Biologics, Inc	22-10-12	CI
Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline	22-05-05	CI
Synthetic Biologics Names Frank Tufaro Chief Operating Officer	22-03-23	MT
Synthetic Biologics, Inc. Announces Management Transitions in Support of Strategic Transformation	22-03-23	CI
Synthetic Biologics, Inc. Announces Executive Changes	20-11-12	CI
Synthetic Biologics, Inc. Appoints Steven A. Shallcross as Chief Executive Officer and Director	18-12-06	CI
Synthetic Biologics, Inc. Announces Executive Changes, Effective December 2018	18-10-10	CI
Synthetic Biologics Announces Management Changes	17-12-05	CI
Synthetics Biologics, Inc. Appoints Dr. Sliman as Chief Medical Officer	17-01-19	CI
Isaac J. Bright Joins Synthetic Biologics as Vice President, Corporate Development	16-05-11	CI
Synthetic Biologics Appoints Deb Mathews as Vice President, Medical Affairs	16-05-09	CI
Synthetic Biologics Inc. Appoints Raymond Stapleton as Senior Vice President of Manufacturing	15-10-01	CI
Klaus Gottlieb Joins Synthetic Biologics Inc. as Vice President, Clinical & Regulatory Affairs, Effective June 22, 2015	15-06-02	CI
Maureen Early Joins Synthetic Biologics Inc. as Vice President, Commercial	15-05-07	CI
Synthetic Biologics Inc. Announces Management Changes	15-05-04	CI
Synthetic Biologics, Inc. Announces Appointments to Clinical Advisory Board	14-10-15	CI
Synthetic Biologics Inc. Forms Clinical Advisory Board to Support Novel C. difficile Preventative Program	14-06-30	CI
Synthetic Biologics Appoints Mark Pimentel, M.D., Chairman of New Irritable Bowel Syndrome Clinical Advisory Board	14-04-14	CI
Synthetic Biologics Inc. Announces Resignation of Steve H. Kanzer, Founder, Board Member and Subsidiary CEO and President	14-02-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders Theriva Biologics, Inc.

Equities

TOVX

US87164U4094

Insiders

Filters